These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30909892)

  • 1. Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
    Blair CM; Walsh NM; Littman BH; Marcoux FW; Baillie GS
    BMC Cancer; 2019 Mar; 19(1):266. PubMed ID: 30909892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase-8A binds to and regulates Raf-1 kinase.
    Brown KM; Day JP; Huston E; Zimmermann B; Hampel K; Christian F; Romano D; Terhzaz S; Lee LC; Willis MJ; Morton DB; Beavo JA; Shimizu-Albergine M; Davies SA; Kolch W; Houslay MD; Baillie GS
    Proc Natl Acad Sci U S A; 2013 Apr; 110(16):E1533-42. PubMed ID: 23509299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE8 controls CD4
    Basole CP; Nguyen RK; Lamothe K; Vang A; Clark R; Baillie GS; Epstein PM; Brocke S
    Cell Signal; 2017 Dec; 40():62-72. PubMed ID: 28851628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance
    Poudel M; Kim G; Bhattarai PY; Shin S; Zaraei SO; Oh CH; Choi HS
    Anticancer Res; 2022 Jun; 42(6):2911-2921. PubMed ID: 35641256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
    Doudican NA; Orlow SJ
    Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
    Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
    Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDE8A runs interference to limit PKA inhibition of Raf-1.
    Maurice DH
    Proc Natl Acad Sci U S A; 2013 Apr; 110(16):6248-9. PubMed ID: 23550163
    [No Abstract]   [Full Text] [Related]  

  • 9. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.
    Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
    Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
    Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
    Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-
    Kim G; Bhattarai PY; Oh CH; Choi HS
    Anticancer Res; 2019 Dec; 39(12):6537-6546. PubMed ID: 31810919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
    Fallahi-Sichani M; Becker V; Izar B; Baker GJ; Lin JR; Boswell SA; Shah P; Rotem A; Garraway LA; Sorger PK
    Mol Syst Biol; 2017 Jan; 13(1):905. PubMed ID: 28069687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-RAF is a therapeutic target in melanoma.
    Karasarides M; Chiloeches A; Hayward R; Niculescu-Duvaz D; Scanlon I; Friedlos F; Ogilvie L; Hedley D; Martin J; Marshall CJ; Springer CJ; Marais R
    Oncogene; 2004 Aug; 23(37):6292-8. PubMed ID: 15208680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
    Ryabaya OO; Malysheva AA; Khochenkova YA; Solomko ES; Khochenkov DA
    Mol Biol (Mosk); 2018; 52(3):466-473. PubMed ID: 29989578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METTL3 induces PLX4032 resistance in melanoma by promoting m
    Bhattarai PY; Kim G; Poudel M; Lim SC; Choi HS
    Cancer Lett; 2021 Dec; 522():44-56. PubMed ID: 34530048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.